FOXA1 and prostate cancer: We used the DHS profiled in prostate cancer cells to identify putative FOXA1 CREs by annotating these regions with five different histone modifications, TF-binding sites and noncoding SNVs profiled in prostate cancer cells and primary prostate tumors.